Non-Biologic DMARDs

DRUG3 trials

Sponsors

Hoffmann-La Roche

Conditions

Juvenile Idiopathic ArthritisRheumatoid Arthritis

Phase 3

A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis

CompletedNCT01987479

Hoffmann-La RocheRheumatoid Arthritis

Start: 2014-01-30End: 2016-05-26Updated: 2017-06-19

A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

CompletedNCT02046616

Hoffmann-La RocheRheumatoid Arthritis

Start: 2014-05-28End: 2016-09-13Updated: 2018-04-13

Unknown Phase

Retrospective Analysis of Pulmonary Arterial Hypertension (PAH) and Related Complications in Juvenile Idiopathic Arthritis (JIA) Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs (DMARDs)

CompletedNCT02784808

Hoffmann-La RocheJuvenile Idiopathic Arthritis

Start: 2000-01-31End: 2012-12-31Updated: 2016-06-08

Related Papers

Major reduction of ultrasound-detected synovitis during subcutaneous tocilizumab treatment: results from a multicentre 24 week study of patients with rheumatoid arthritis

Scandinavian Journal of Rheumatology2021-01-198 citations

Rheumatoid arthritis patients with predominantly tender joints rarely achieve clinical remission despite being in ultrasound remission

Rheumatology Advances in Practice2021-01-017 citations

Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis

Lara D. Veeken2018-11-2110 citations

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries

Lara D. Veeken2017-10-3137 citations